Europe's Cancer Immunotherapy Meeting

CIMT ANNUAL MEETING, MAINZ/GERMANY, MAY 10-12, 2021 − ONLINE AND CONNECTED

In 2021, in consideration of the ongoing COVID-19 pandemic, the largest European meeting focused on cancer immunotherapy research and development will be held in a virtual format.

With this move, we will take the opportunity to provide international participants with high-level scientific learning and knowledge exchange focused on cancer immunotherapy regardless of their location or any travel restrictions.

The CIMT program committee is preparing plenary sessions ranging from pre-clinical research to clinical development on the topics of neoantigens, cellular therapy, computational immunology, tumor microenvironment, combination therapies, regulatory research, therapeutic vaccination, and immunoguiding. Special emphasis will be put on discussion groups and question-and-answer sessions to provide room for personal interactions.
The plenary sessions will be complemented by an eTalk exhibit. Top scientific eTalks will be selected for poster awards.

As part of a dedicated COVID-19 − immuno-oncology cross-talk session, Ugur Sahin of BioNTech will deliver the keynote on the scientific journey of developing an mRNA coronavirus vaccine in 10 months.

Every year since 2002, the CIMT Annual Meeting has been connecting the global cancer immunotherapy community in the heart of Europe. As the largest science-driven, not-for-profit event in Europe focusing on cancer immunology and immunotherapy, CIMT has fostered the development of immunotherapies by offering a platform addressing the latest advances, successes and challenges in the field.

 

2021 Scientific Planning Committee

Özlem Türeci
BioNtech, Mainz/Germany

Johanna Olweus
Oslo University Hospital, Oslo/Norway

Sine Reker Hadrup
Denmark Technical University, Copenhagen/Denmark

Marij Welters
Leiden University Medical Center, Leiden/The Netherlands

Sebastian Kreiter
TRON-Translational Oncology, Mainz/Germany; Head of CIMT Management Board

Mustafa Diken
TRON-Translational Oncology, Mainz/Germany; CIMT Scientific Secretary

Harpreet Singh
Immatics, Tübingen/Germany